Monopar Therapeutics MNPR EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's EPS (basic)?
- Monopar Therapeutics (MNPR) reported EPS (basic) of -$0.46 in Q1 2026.
- How has Monopar Therapeutics's EPS (basic) changed year-over-year?
- Monopar Therapeutics's EPS (basic) decreased by 21.1% year-over-year, from -$0.38 to -$0.46.
- What is the long-term trend for Monopar Therapeutics's EPS (basic)?
- Over 3 years (2022 to 2025), Monopar Therapeutics's EPS (basic) has grown at a 30.6% compound annual growth rate (CAGR), from -$0.83 to -$1.85.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.